The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics Limited reported a significant increase in losses for the half-year ended December 31, 2024, with a 216.9% rise in losses attributable to owners, totaling $2,857,887. Despite the financial setback, the company’s net tangible assets per ordinary security improved from (1.09) cents to (0.35) cents, indicating a potential stabilization in asset valuation. No dividends were declared for the current or previous financial periods, and the company’s financial statements were reviewed with a material uncertainty regarding its going concern status.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its proprietary CAR T cell therapy platform to address unmet medical needs in oncology.
Average Trading Volume: 4,603,630
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.37M
Learn more about CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com